The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Brüning, Ansgar ^a   Rahmeh, Martina ^a   Gingelmaier, Andrea ^a   Friese, Klaus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AXXORA; CASPASE 3; CASPASE 7; CASPASE 8; NELFINAVIR; PROTEIN MCL 1; SORAFENIB; UNCLASSIFIED DRUG; BENZENESULFONIC ACID DERIVATIVE; CYCLIN B; CYCLIN DEPENDENT KINASE 1; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN BCL 2; PYRIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL DAMAGE; CELL DEATH; CELL STRAIN HL 60; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LEUKEMIA CELL LINE; MEMBRANE STABILIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN EXPRESSION; UPREGULATION; CELL CYCLE; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA; METABOLISM; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; BENZENESULFONATES; BONE MARROW CELLS; CASPASE 8; CDC2 PROTEIN KINASE; CELL CYCLE; CELL LINE, TUMOR; CYCLIN B; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MITOCHONDRIAL MEMBRANES; NELFINAVIR; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; UP-REGULATION;

EID: 77649317105     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-19     Document Type: Article

References (36)

1. Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS, Dennis PA. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 2007, 13:5183-5184. 10.1158/1078-0432.CCR-07-0161, 17785575.
2. Pyrko P, Kardosh A, Wang W, Xiong W, Schönthal AH, Chen TC. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res 2007, 67:10920-10928. 10.1158/0008-5472.CAN-07-0796, 18006837.
3. Cohen J. HIV drug shows promise as potential cancer treatment. Science 2007, 317:1305. 10.1126/science.317.5843.1305, 17823319.
4. Plastaras JP, Vapiwala N, Ahmed MS, Gudonis D, Cerniglia GJ, Feldman MD, Frank I, Gupta AK. Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. Cancer Biol Ther 2008, 7:628-635.
5. Brunner TB, Geiger M, Grabenbauer GG, Lang-Welzenbach M, Mantoni TS, Cavallaro A, Sauer R, Hohenberger W, McKenna WG. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2008, 26:2699-2706. 10.1200/JCO.2007.15.2355, 18509182.
6. Chow WA, Jiang C, Guan M. Anti-HIV drugs for cancer therapeutics: back to the future?. Lancet Oncol 2009, 10:61-71. 10.1016/S1470-2045(08)70334-6, 19111246.
7. Brüning A, Vogel M, Burger P, Rahmeh M, Gingelmaier A, Friese K, Lenhard M, Burges A. Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells. Biochem Biophys Res Commun 2008, 377:1309-1314. 10.1016/j.bbrc.2008.10.167, 19000651.
8. Brüning A, Burger P, Vogel M, Rahmeh M, Gingelmaiers A, Friese K, Lenhard M, Burges A. Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis. Cancer Biol Ther 2009, 8:226-232.
9. Kim R, Emi M, Tanabe K. Role of mitochondria as the gardens of cell death. Cancer Chemother Pharmacol 2006, 57:545-553. 10.1007/s00280-005-0111-7, 16175394.
10. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther 2004, 4:139-163.
11. Leber B, Lin J, Andrews DW. Embedded together: the life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis 2007, 12:897-911. 10.1007/s10495-007-0746-4, 17453159.
12. Chipuk JE, Green DR. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?. Trends Cell Biol 2008, 18:157-164. 10.1016/j.tcb.2008.01.007, 18314333.
13. McDonnell TJ, Beham A, Sarkiss M, Andersen MM, Lo P. Importance of the Bcl-2 family in cell death regulation. Experientia 1996, 52:1008-1017. 10.1007/BF01920110, 8917732.
14. Wuillème-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H, Harousseau JL, Amiot M, Bataille R. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005, 19:1248-1252. 10.1038/sj.leu.2403784, 15902294.
15. Weng C, Li Y, Xu D, Shi Y, Tang H. Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem 2005, 280:10491-10500. 10.1074/jbc.M412819200, 15637055.
16. Bae J, Leo CP, Hsu SY, Hsueh AJ. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J Biol Chem 2000, 275:25255-25261. 10.1074/jbc.M909826199, 10837489.
17. Le Gouill S, Podar K, Harousseau JL, Anderson KC. Mcl-1 regulation and its role in multiple myeloma. Cell Cycle 2004, 3:1259-1262.
18. Gandhi V, Balakrishnan K, Chen LS. Mcl-1: the 1 in CLL. Blood 2008, 112:3538-3540. 10.1182/blood-2008-07-170241, 18948586.
19. Schindlbeck C, Stellwagen J, Jeschke U, Karsten U, Rack B, Janni W, Jückstock J, Tulusan A, Sommer H, Friese K. Immunomagnetic enrichment of disseminated tumor cells in bone marrow and blood of breast cancer patients by the Thomsen-Friedenreich-Antigen. Clin Exp Metastasis 2008, 25:233-240. 10.1007/s10585-007-9137-z, 18185913.
20. Guo Y, Srinivasula SM, Druilhe A, Fernandes-Alnemri T, Alnemri ES. Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J Biol Chem 2002, 277:13430-1347. 10.1074/jbc.M108029200, 11832478.
21. Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol 2009, 220:214-221. 10.1002/jcp.21753, 19288493.
22. Warr MR, Shore GC. Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med 2008, 8:138-147. 10.2174/156652408783769580, 18336294.
23. Brüning A, Burger P, Vogel M, Gingelmaier A, Friese K, Burges A. Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib. Invest New Drugs 2009, 10.1007/s10637-009-9281-1.
24. Phenix BN, Lum JJ, Nie Z, Sanchez-Dardon J, Badley AD. Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood 2001, 98:1078-1085. 10.1182/blood.V98.4.1078, 11493454.
25. Weaver JG, Tarze A, Moffat TC, Lebras M, Deniaud A, Brenner C, Bren GD, Morin MY, Phenix BN, Dong L, Jiang SX, Sim VL, Zurakowski B, Lallier J, Hardin H, Wettstein P, van Heeswijk RP, Douen A, Kroemer RT, Hou ST, Bennett SA, Lynch DH, Kroemer G, Badley AD. Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor. J Clin Invest 2005, 115:1828-1838. 10.1172/JCI22954, 1142110, 15937550.
26. Hisatomi T, Nakazawa T, Noda K, Almulki L, Miyahara S, Nakao S, Ito Y, She H, Kohno R, Michaud N, Ishibashi T, Hafezi-Moghadam A, Badley AD, Kroemer G, Miller JW. HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice. J Clin Invest 2005, 118:2025-2038.
27. Singh VP, Bren GD, Algeciras-Schimnich A, Schnepple D, Navina S, Rizza SA, Dawra RK, Saluja AK, Chari ST, Vege SS, Badley AD. Nelfinavir/ritonavir reduces acinar injury but not inflammation during mouse caerulein pancreatitis. Liver Physiol 2009, 296:G1040-6.
28. Vlahakis SR, Bennett SA, Whitehead SN, Badley AD. HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo. Apoptosis 2007, 12:969-977. 10.1007/s10495-007-0755-3, 17453162.
29. Rizza SA, Badley AD. HIV protease inhibitors impact on apoptosis. Med Chem 2008, 4:75-79. 10.2174/157340608783331443, 18220972.
30. Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 2004, 64:1757-1564. 10.1158/0008-5472.CAN-03-2546, 14996737.
31. Brüning A, Friese K. Benefits and adverse effects of anti-emetic glucocorticoids in cancer. Cancer Biol Ther 2006, 5:921-922.
32. Regazzi MB, Villani P, Maserati R, Seminari E, Pan A, LoCaputo F, Gambarana E, Fiocchi C. Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients. J Antimicrob Chemother 2000, 45:343-347. 10.1093/jac/45.3.343, 10702554.
33. Crum-Cianflone NF, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, Fraser S, Roediger MP, Agan B, Wegner S. The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2009, 51:305-309. 10.1097/QAI.0b013e3181aa13c7, 19412116.
34. Markowitz M, Conant M, Hurley A, Schluger R, Duran M, Peterkin J, Chapman S, Patick A, Hendricks A, Yuen GJ, Hoskins W, Clendeninn N, Ho DD. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis 1998, 177:1533-1540. 10.1086/515312, 9607830.
35. Bardsley-Elliot A, Plosker GL. Nelfinavir: an update on its use in HIV infection. Drugs 2000, 59:581-620. 10.2165/00003495-200059030-00014, 10776836.
36. Bartlett JA, Fath MJ, Demasi R, Hermes A, Quinn J, Mondou E, Rousseau F. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006, 20:2051-2064. 10.1097/01.aids.0000247578.08449.ff, 17053351.